A well-known
blood-pressure medicine promoted by Bristol-Myers Squibb Corp. and Sanofi-Aventis SA failed in a huge study to show a profit among patients with a ordinary and hard-to-treat form of
heart failure.
Researchers stated the results displayed the want for more facts about mechanisms following the disease that accounts for 500,000 hospital admissions yearly in the U.S. -- and that includes both physically weakening and an significant driver of health-care costs. Patients in the revise reveal about half of the five million Americans diagnosed are with
heart failure. Such patients as well have hearts with usual pumping capacity, but though are at high risk of death and cardiovascular-related hospital admissions.